
3 Questions Decision-Makers Raise About FDA Regulatory and Compliance: Premarket approval timelines, post-market adverse event reporting, and warning label adequacy.In-house counsel and compliance officers managing FDA regulatory and compliance obligations face a landscape where regulatory expectations shift faster than many organizations can adapt. The Food and Drug Administration oversees products ranging from pharmaceuticals and medical devices to dietary supplements and cosmetics, each with distinct compliance pathways and enforcement priorities. A single misstep in premarket submissions, labeling, or adverse event reporting can trigger warning letters, consent decrees, or product seizures. This article examines the legal risks that most frequently trigger enforcement action and the strategic decisions that should inform your compliance posture now.
Lire la suite

A memorandum of understanding outlines mutual intentions, while a contract creates legally enforceable obligations under New York contract law. Business terms often blur these legal boundaries during preliminary negotiations. Clear distinction prevents unexpected liabilities.
Lire la suite

3 Bottom-Line Points on Compliance Management from Counsel: Regulatory deadlines create enforcement exposure, internal audits reveal gaps before regulators do, documentation standards vary by industryCompliance management in a modern business environment requires more than reactive problem-solving. Organizations face overlapping regulatory frameworks, evolving enforcement priorities, and substantial penalties for lapses. The stakes are real: a single missed deadline or inadequate control can trigger investigations, fines, reputational damage, and operational disruption. This article addresses the strategic decisions in-house counsel and business decision-makers should evaluate now to build defensible compliance infrastructure and reduce legal risk.
Lire la suite

3 Questions Decision-Makers Raise About Top M&A Law Firm Matters: Due diligence scope and timeline, representation and indemnification exposure, regulatory clearance delays.Mergers and acquisitions involve intricate legal, financial, and operational complexities that demand strategic foresight from decision-makers. Whether you are an in-house counsel, a business owner, or a transaction manager, understanding the critical legal risks in top M&A law firm engagements shapes how you navigate deal structure, manage vendor relationships, and allocate resources. The stakes are high: a missed regulatory filing, an inadequate indemnification clause, or a poorly scoped due diligence process can unwind months of negotiation and expose your organization to unforeseen liability.
Lire la suite

Which courthouse you are in changes how your expert is tested. New York state courts apply Frye, not Daubert. The question is whether the methodology is generally accepted in the relevant field — not whether a judge finds it reliable. Since Parker, courts also examine whether the foundation for the opinion is adequate. In federal court the same expert faces Rule 702 and a different inquiry entirely. CPLR 3101(d) requires no written report. Disclosure is limited to the expert's identity, subject matter, the substance of the opinions, qualifications, and a summary of the grounds. Compared with federal practice this is thin — which means you often learn how the other side's expert reached a number at the deposition, or later. Timing is set by the court, not the statute. Preliminary conference orders and individual rules control, and the Commercial Division has its own schedule. There is no default deadline to rely on. Before methodology, there is Kenford. Lost profits must be proven with reasonable certainty, caused by the breach, and within the contemplation of the parties at contracting. New business claims face particular difficulty. A well-constructed damages model does not cure a claim that fails this test — it is a question about the claim, not the expert.
Lire la suite

3 Questions Decision-Makers Raise About Exclusive Sales Contracts: Territorial scope and duration limits, non-compete enforceability, termination and damages exposure.An exclusive sales contract grants one party the sole right to sell or distribute a product or service within a defined territory or customer base for a specified period. From a practitioner's perspective, these agreements create significant legal exposure because the parties often hold conflicting expectations about what exclusive actually means in practice, and disputes over performance, territory definition, and early termination can escalate quickly into costly litigation. Decision-makers should understand that exclusive sales contracts are heavily regulated under antitrust law, state contract law, and the Uniform Commercial Code, and that courts interpret these agreements with particular scrutiny when they restrict competition or market access.
Lire la suite
